Mer­ck KGaA spin­out gets first fund­ing to bring dual-act­ing can­cer mol­e­cules in­to the clin­ic

Two and a half years af­ter launch, Mer­ck KGaA spin­out iOnc­tura is get­ting its first ma­jor round of fund­ing.

The on­col­o­gy start­up raised €15 mil­lion ($16.6 mil­lion) to put its lead drug in­to the clin­ic and get its sec­ond drug past IND-en­abling tests. INKEF Cap­i­tal and VI Part­ners co-led the round and were joined by the biotech’s long­time backer M Ven­tures, an arm of Mer­ck KGaA, and Schroder Ad­veq.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.